NRAS Q61K

Clinical trials for NRAS Q61K explained in plain language.

Never miss a new study

Get alerted when new NRAS Q61K trials appear

Sign up with your email to follow new studies for NRAS Q61K, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New targeted drug hopes to shrink Hard-to-Treat melanoma

Disease control Recruiting now

This early-stage study tests a new drug called RLY-8161 in people with advanced melanoma or other solid tumors that have a specific NRAS gene mutation. The main goals are to find a safe dose and see if the drug can shrink tumors. About 35 participants will take the drug by mouth,…

Matched conditions: NRAS Q61K

Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control

Last updated May 26, 2026 10:05 UTC

NRAS Q61K

Get alerted when new NRAS Q61K trials appear

New targeted drug hopes to shrink Hard-to-Treat melanoma